Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2022, quadraScope is a venture capital firm that operates from Boston, Massachusetts, and Tel Aviv, Israel. The firm focuses on the longevity healthcare sector, investing in companies that develop pharmaceuticals, diagnostics, software, equipment, and devices aimed at disease treatment and prevention through biological age reversal. By leveraging the strengths of these two major biotech hubs, quadraScope identifies and supports innovative solutions in the field of aging and healthspan extension.
quadraScope has built a portfolio of 12 companies, showcasing its commitment to advancing longevity technologies. The firm is led by a team of experienced professionals from medicine, science, and finance, including several venture partners with advanced degrees. This diverse expertise allows quadraScope to provide hands-on support and strategic guidance to its portfolio companies, enhancing their chances of success in a competitive market.
Notable milestones for quadraScope include its active participation in industry events, such as the upcoming JP Morgan Healthcare Conference in January 2026, which focuses on biotech and finance. The firm is recognized for its deep expertise in longevity and healthcare, making it a compelling partner for startups in these sectors.
quadraScope specializes in investing in companies that address the biological basis of aging, particularly in the field of biogerontology. The firm targets a wide range of investment stages, from pre-seed to Series F and growth equity, allowing it to engage with startups at various points in their development. The primary sectors of interest include biotech, healthcare, and longevity, with a specific focus on innovative solutions that tackle the hallmarks of aging, such as genomic instability, telomere attrition, epigenetic alterations, and chronic inflammation.
The firm seeks to enhance healthspan and prevent age-related diseases through its investments. quadraScope looks for founders who are passionate about advancing longevity technologies and who possess a strong understanding of their respective fields. The firm prefers to engage in deal structures that allow for active involvement and support, fostering a collaborative relationship with portfolio companies.
Geographically, quadraScope focuses on North America and Asia, leveraging its dual presence in Boston and Tel Aviv to source innovative ideas and technologies. This strategic positioning enables the firm to tap into the rich biotech ecosystems in both regions, enhancing its ability to identify promising investment opportunities.
quadraScope's portfolio consists of 12 notable companies, each contributing to the longevity healthcare sector:
This diverse portfolio reflects quadraScope's commitment to supporting innovative solutions in the longevity healthcare space, with a focus on addressing age-related diseases and enhancing healthspan.
Fiona Miller: Managing Partner & Founder. Fiona has over 40 years of experience in technology entrepreneurship and venture capital. She has led investments since July 2021 and has a track record of successful exits, including a 12x exit. Fiona is also the founder and CEO of octoScope, which was sold to Spirent Communications in 2021.
José Navarro-Betancourt, MD, PhD: Scientific Director. José brings extensive expertise in biogerontology and healthcare, guiding the firm's scientific evaluation of potential investments.
Eve Voronkina: Financial Analyst. Eve supports the financial analysis and due diligence processes for potential investments.
Nir Barzilai, MD: Venture Partner. Nir is a prominent figure in aging research and contributes his insights to the firm's investment strategy.
Aubrey de Grey, PhD: Venture Partner. Aubrey is known for his work in the field of longevity and aging, providing valuable expertise to the firm.
Carmela Abraham, PhD: Venture Partner. Carmela has a strong background in neuroscience and aging research, enhancing the firm's scientific rigor.
Robert Cargill, PhD: Venture Partner. Robert's expertise in biotechnology and aging complements the firm's focus on innovative solutions.
Diane Seimetz, PhD: Venture Partner. Diane brings experience in drug development and aging research to the team.
Reason: Venture Partner. Reason contributes to the firm's investment strategy with a focus on innovative healthcare solutions.
Nikola Markov, PhD: Venture Partner. Nikola's background in biotechnology and aging research supports the firm's investment thesis.
Miri Polachek: Venture Partner. Miri provides insights into the biotech landscape, enhancing the firm's investment decision-making.
Nico Helling: Venture Partner. Nico's expertise in healthcare and technology informs the firm's investment strategy.
Frank Wellens: Venture Partner. Frank contributes to the firm's focus on innovative healthcare solutions.
Daniel Fylstra: Venture Partner. Daniel's background in biotechnology and healthcare supports the firm's investment thesis.
Lan Clark: Venture Partner. Lan brings experience in venture capital and healthcare to the team.
José Cordeiro, PhD: Venture Partner. José's expertise in aging research enhances the firm's scientific evaluation of potential investments.
Noriko Yokoi, PhD: Venture Partner. Noriko contributes to the firm's focus on innovative solutions in longevity healthcare.
To pitch quadraScope, founders should send an email to info@quadrascope.com. It is important to include a comprehensive pitch deck that outlines the startup's mission, technology, market opportunity, and team background. Founders should also highlight any scientific validation or partnerships that strengthen their proposal.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can enhance the likelihood of a favorable review. Engaging with quadraScope during industry events may also provide additional opportunities for connection.
quadraScope has been actively engaging in the healthcare investment space, with plans to participate in the JP Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, CA. This event focuses on biotech and finance, providing an opportunity for the firm to connect with industry leaders and showcase its portfolio companies.
Since its founding in 2022, quadraScope has built a diverse portfolio of 12 companies, reflecting its commitment to advancing longevity technologies. The firm continues to explore new investment opportunities in the longevity healthcare sector, leveraging its dual presence in Boston and Tel Aviv to identify innovative solutions.
What investment criteria does quadraScope look for?
quadraScope targets companies that address the biological basis of aging, particularly in biogerontology. The firm invests in various stages, from pre-seed to Series F and growth equity, focusing on innovative solutions in biotech and healthcare.
How can founders apply or pitch to quadraScope?
Founders can pitch to quadraScope by sending an email to info@quadrascope.com. It is recommended to include a detailed overview of the startup, its technology, and the team.
What makes quadraScope different from other investors?
quadraScope specializes in longevity healthcare investments, leveraging expertise in biogerontology and a strong network in the biotech ecosystem. The firm provides hands-on support and strategic guidance to its portfolio companies.
What is quadraScope's geographic scope?
The firm focuses on investments in North America and Asia, leveraging its presence in Boston and Tel Aviv to identify innovative solutions in the longevity healthcare sector.
What is quadraScope's approach to post-investment involvement?
quadraScope actively participates in the growth of its portfolio companies by providing strategic guidance, industry connections, and support in navigating the biotech landscape.
What is the typical check size for quadraScope?
While specific check sizes are not disclosed, quadraScope is known for making initial investments in early-stage companies, often participating in syndicated rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.